Erik P. Castle, MD
The prostate cancer paradigm continues to evolve with emerging treatment and imaging modalities, but risk stratification is the key to creating an appropriate management strategy—even between very low-risk and low-risk patients, explains Erik P. Castle, MD.
State of the Science Summit™ on Genitourinary Cancers, Castle, consultant, Department of Urology, professor of urology, Mayo Clinic, spoke on the importance of risk stratifying low- and intermediate-risk localized prostate cancers.
OncLive: Please provide an overview of your presentation.
I spoke about risk stratification for both low- and intermediate-risk prostate cancer, primarily clinically localized cancer. This is the kind that one might be trying to decide whether you’re going to pursue active surveillance or some sort of definitive treatment. You can even sub-stratify low risk into very low-risk and low-risk disease.
... to read the full story